LAS VEGAS, June 9, 2020
LAS VEGAS, June 9, 2020 /PRNewswire/ -- As per DelveInsight's analysis, Prostate Cancer Market Size in the 7MM is anticipated to grow in the coming decade owing to increasing prostate cancer prevalence, rich pipeline, incremental healthcare spending and over a dozen of pharma companies working to fuel the market growth.
DelveInsight has announced the addition of a new market research report - Prostate cancer Market Insight, Epidemiology and Market Forecast -2030 to its portfolio.
Request for Sample Pages: https://www.delveinsight.com/sample-request/prostate-cancer-market
A malignancy of the prostate gland, Prostate cancer is the fourth most commonly prevalent form of cancer globally and the third most prevalent form in the US.
Prostate Cancer Epidemiology
The epidemiology forecast model of Prostate Cancer for the 7MM is based on the analysis of the prevalent and diagnosed prevalent cases of prostate cancer. Latter is further segmented into prostate cancer cases by age, clinical stages at diagnosis, non-metastatic and metastatic cases of HSPC/CSPC, and CRPC, and treated pool of non-metastatic and metastatic HSPC/CSPC and CRPC.
The Prostate Cancer epidemiology for 7MM for the study period of 2017-30 is segmented into:
As per the DelveInsight's Prostate Cancer Market Report, Prostate cancer is frequently diagnosed among men of the age group 65–74 years. Most of the cases of clinical-stage wise Prostate Cancer were of localized stage that accounted approximately 60% of the total diagnosed prevalent cases of prostate cancer in 2017.
Prostate Cancer Market
Prostate Cancer Market has several treatment options available to treat this condition in the 7MM, such as Active surveillance, Radiation therapy, Radical Prostatectomy (RP), Hormone therapy, Chemotherapy, and Immunotherapy. Prostate Cancer Market comprises of Jevtana (cabazitaxel) in combination with prednisone, Zytiga in combination with prednisone, after or before docetaxel therapy for different forms of cancer.
Recently, at 54th virtual meeting of ASCO, the results from the study sponsored by Bayer evaluating NUBEQA (darolutamide) plus androgen deprivation therapy (ADT) demonstrated significantly improve overall survival (OS) compared to ADT alone, in men with non-metastatic castration-resistant prostate cancer (nmCRPC).
Prostate Cancer has a high curable rate if detected early; despite considerable progress in the development of novel therapeutic interventions, the introduction of effective diagnostic still lags. Therefore, the establishment of better diagnostic tools is needed.
Among the 7MM countries, the highest market size of Prostate Cancer was occupied by the United States, followed by Germany in Europe and Japan in 2017.
The Prostate Cancer Market is segmented by Distribution of Prostate Cancer in 2017 and 2030, size of the market by types of prostate cancer, therapy wise market size of castrate-resistant prostate cancer (CRPC), and therapy wise market size of castration-sensitive prostate cancer (CSPC).
Prostate Cancer Marketed Drugs
Prostate Cancer Emerging Drugs
At present, several companies have indulged themselves in initiating clinical trials that investigate new treatments options or studying how to use existing treatment options better.
The current developmental Prostate Cancer pipeline is very robust including late- phase diverse group of drug classes such as PARPi, PD-L1i, AKTi. Besides, a strong pipeline, uptake of potential emerging therapies with better clinical profile, specially targeting the mutations like PARP inhibitors (i.e. BRCA mutation) are major factors driving the Prostate Cancer Market forward. Furthermore, due to an increase in the demand for the better treatment due to the rising Prostate Cancer prevalence, rising geriatric population, incremental healthcare spending, and rising awareness of the disease are other market drivers behind the changing dynamics of the Prostate Cancer market that is anticipated to change by 2030.
Conclusively, the positive results of investigational products and a robust pipeline for Prostate Cancer will bring a positive ray of hope for a better treatment pattern in the market in the coming years. The current scenario also anticipates a positive shift in the market for a study period (2017–2030).
Click to know more about the report offerings: https://www.delveinsight.com/report-store/prostate-cancer-market
Scope of the Report
Reason to purchase
Table of Contents
Executive Summary of Prostate Cancer
SWOT Analysis of Prostate Cancer
Prostate Cancer Market Overview at a Glance
Prostate Cancer Disease Background and Overview
Prostate Cancer Diagnosis
Prostate Cancer Epidemiology and Patient Population
Country-wise Prostate Cancer Epidemiology
Current Prostate Cancer Treatment Practices
Guideline of Prostate Cancer
Unmet Needs of Prostate Cancer
Prostate Cancer Marketed Therapies
Prostate Cancer Emerging Therapies
Prostate Cancer Seven Major Market Analysis
7MM Prostate Cancer Market Size
Prostate Cancer Market Access and Reimbursement
Prostate Cancer Market Drivers
Prostate Cancer Market Barriers
Request for a WebEx demonstration of the report: https://www.delveinsight.com/report-store/prostate-cancer-market
DelveInsight's "Metastatic Hormone Refractory Prostate Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Metastatic Hormone Refractory Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Hormone Refractory Prostate Cancer market trends in the 7MM.
DelveInsight's 'Castrate-Sensitive Prostate Cancer (CSPC) Market Insights, Epidemiology and Market Forecast - 2030' report delivers an in-depth understanding of the CSPC, historical and forecasted epidemiology as well as the CSPC market trends in the 7MM.
DelveInsight's 'Castrate-resistant Prostate Cancer (CRPC) -Market Insights, Epidemiology and Market Forecast - 2030' report delivers an in-depth understanding of the CRPC, historical and forecasted epidemiology as well as the CRPC market trends the 7MM.
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.
Get in touch for customizable solutions.